Lantern Pharma reports LP-300 shows 8.3-month median PFS in EGFR L858R NSCLC trial

• Lantern Pharma scheduled an FDA Type C meeting for mid-May 2026 to discuss changes to ongoing Phase 2 HARMONIC trial for investigational lung cancer drug LP-300.
• Emerging HARMONIC data have already been compiled through an April 13, 2026 cutoff, showing patients with EGFR L858R-mutant NSCLC had longer disease control than other EGFR-mutant groups following failure of targeted therapy.
• Lantern plans to narrow future enrollment to EGFR L858R patients, reflecting a shift toward a biomarker-focused development path in a high-need post-TKI setting.
• Company also seeks to revise trial design to a single-arm Phase 2 study, citing a changing standard of care that undermines feasibility of continued randomization.
• Lantern aims to extend LP-300 dosing from 6 to 8 cycles, supported by signals of improved outcomes with longer treatment duration without added clinically meaningful toxicity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604200805BIZWIRE_USPR_____20260420_BW812445) on April 20, 2026, and is solely responsible for the information contained therein.